CN113577140A - Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof Download PDFInfo
- Publication number
- CN113577140A CN113577140A CN202110853779.1A CN202110853779A CN113577140A CN 113577140 A CN113577140 A CN 113577140A CN 202110853779 A CN202110853779 A CN 202110853779A CN 113577140 A CN113577140 A CN 113577140A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- treating
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 25
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 25
- 241000132012 Atractylodes Species 0.000 claims abstract description 24
- 235000006533 astragalus Nutrition 0.000 claims abstract description 24
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 22
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 21
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 21
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 21
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000007126 Codonopsis pilosula Species 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 240000004510 Agastache rugosa Species 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 9
- 241000756943 Codonopsis Species 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 28
- 241000711573 Coronaviridae Species 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000011580 syndromic disease Diseases 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 5
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 230000000295 complement effect Effects 0.000 abstract description 2
- 241001570521 Lonicera periclymenum Species 0.000 description 21
- 210000004072 lung Anatomy 0.000 description 21
- 210000000952 spleen Anatomy 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 206010011224 Cough Diseases 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 12
- 208000026435 phlegm Diseases 0.000 description 12
- 230000007812 deficiency Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 9
- 208000000059 Dyspnea Diseases 0.000 description 8
- 206010013975 Dyspnoeas Diseases 0.000 description 8
- 241001673966 Magnolia officinalis Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 208000017574 dry cough Diseases 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000022531 anorexia Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 210000004233 talus Anatomy 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 241001529821 Agastache Species 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 241000576429 Forsythia suspensa Species 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010038687 Respiratory distress Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 2
- 241000092665 Atractylodes macrocephala Species 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- STRABSCAWZINIF-UHFFFAOYSA-N Juniper camphor Chemical compound C1CCC(C)(O)C2CC(=C(C)C)CCC21C STRABSCAWZINIF-UHFFFAOYSA-N 0.000 description 2
- 244000167230 Lonicera japonica Species 0.000 description 2
- 235000017617 Lonicera japonica Nutrition 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 2
- 229960005174 ambroxol Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- -1 baicalein glucoside Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- STRABSCAWZINIF-RBSFLKMASA-N (-)-Eudesm-7(11)-en-4alpha-ol Natural products C1CC[C@@](C)(O)[C@@H]2CC(=C(C)C)CC[C@]21C STRABSCAWZINIF-RBSFLKMASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- QIMGUQIHCNDUKU-UHFFFAOYSA-N 2-[[6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OCCC=2C=C(O)C(O)=CC=2)O1 QIMGUQIHCNDUKU-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 235000010686 Agastache rugosa Nutrition 0.000 description 1
- 240000003870 Ageratum houstonianum Species 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000266855 Astragalus mongholicus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 240000002505 Pogostemon cablin Species 0.000 description 1
- 235000011751 Pogostemon cablin Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241001162994 Rugosus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000010007 Xuebijing Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- HWXIGFIVGWUZAO-UHFFFAOYSA-N doxofylline Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CC1OCCO1 HWXIGFIVGWUZAO-UHFFFAOYSA-N 0.000 description 1
- 229960004483 doxofylline Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- OMZHXQXQJGCSKN-UHFFFAOYSA-N ethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-(phenylsulfanylmethyl)-1h-indol-1-ium-3-carboxylate;chloride Chemical compound Cl.CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 OMZHXQXQJGCSKN-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930189432 forsythoside Natural products 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100001229 severe poisoning Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating common and light patients and asymptomatic infected persons of new coronary pneumonia, a preparation method of the composition and application of the composition in preparation of a medicine for treating the new coronary pneumonia, and belongs to the technical field of traditional Chinese medicine treatment of the new coronary pneumonia. The composition comprises the following raw materials in parts by weight: 13-28 parts of astragalus membranaceus, 6-25 parts of fried bighead atractylodes rhizome, 7-24 parts of divaricate saposhnikovia root, 4-26 parts of honeysuckle, 7-27 parts of fructus forsythiae, 6-23 parts of mangnolia officinalis and 3-18 parts of honey-fried licorice root. The traditional Chinese medicine composition has complete monarch, minister, assistant and guide components, precise compatibility and complementary effects, and has the functions of tonifying qi, detoxifying, clearing damp and relieving exterior syndrome. The traditional Chinese medicine composition has the advantages of relieving both exterior and interior, and treating both diseases simultaneously, and has obvious curative effect on light and common patients with the novel coronavirus pneumonia.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine treatment of new coronary pneumonia, and particularly relates to a traditional Chinese medicine composition for treating common and light patients and asymptomatic infected persons of new coronary pneumonia, a preparation method of the composition, and application of the composition in preparation of a medicine for treating new coronary pneumonia.
Background
The novel coronavirus pneumonia (COVID-19) is an acute respiratory infectious disease caused by 2019 novel coronavirus (2019-nCOV) infection. The world health organization announced 2019-nCOV-evoked COVID-19 as a public health safety emergency of international social concern. Compared with Severe Acute Respiratory Syndrome (SARS) and other infectious respiratory diseases, the novel coronavirus is mainly transmitted by respiratory droplets, close contact and aerosol, and is faster and stronger in infectivity. The novel coronavirus causes COVID-19 to be attacked and further aggravates the disease condition mainly by directly invading lung tissues, inhibiting cellular immune function, immune crosstalk, apoptosis, abnormal cell metabolism, inflammation storm and the like, has flexible gene recombination and quick adaptability, and can obtain genome segments of hundreds or thousands of base pairs from the other side when two different coronaviruses collide so as to increase self ecological sites and become a new virus, so that the treatment becomes more and more troublesome. Therefore, the significance of preventing and treating the new coronary pneumonia in time is great. The novel coronavirus pneumonia is mainly manifested by fever, dry cough, debilitation and the like, and a few patients are accompanied with upper respiratory tract and digestive tract symptoms such as nasal obstruction, watery nasal discharge, diarrhea and the like. Severe cases often develop dyspnea after 1 week, and severe cases rapidly progress to acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis and coagulation dysfunction, multiple organ failure, and the like. According to the previous and existing cases, the new coronary pneumonia patients mostly adopt light and common types, the conventional treatment of western medicine and the like does not achieve good effect, and the critical rate and the death rate are increased due to lung infection. The most urgent task at present is therefore to develop further effective treatments, eventually leading to effective control of this severe viral infection.
Symptoms of new coronary patients mainly include fever, fatigue, cough, shortness of breath, respiratory distress, etc., accompanied by a decrease in white blood cell count (WBC), lymphopenia, an increase in C-reactive protein (CRP), and/or hypoxemia, chest CT showing a mottled or frosty turbidity in both lungs, and severe infections may show multiple organ failure or even death. The medicine is high in harmfulness, and no specific medicine exists for patients with new coronary pneumonia at present. Modern medical treatment mainly aims at symptomatic support treatment, keeping respiratory tract unobstructed and supporting circulation, but a special medicament for the disease is always lacked, so that the search for more effective treatment medicaments becomes an urgent task.
The first aid thought of traditional Chinese medicine is far from epidemic, and ancient books such as Shang Han Lun, Wen Bing and pestilence Lun and Primary disease have recorded the epidemic-resisting trails of traditional Chinese medicine. The epidemic outbreak is early, the traditional Chinese medicine actively participates in treatment in the whole process, the unique syndrome differentiation treatment system and the multi-target treatment effect of the prescription and the medicine obtain more obvious curative effect in fighting the epidemic situation, and the main treatment principle is as follows: detoxify and resolve dampness, avoid dirty and resolve turbidity, clear heat and relieve asthma, change from constant to constant and make the three reasons suitable. The traditional Chinese medicine is precious wealth in China, the strength of the traditional Chinese medicine is fully known, the value of the traditional Chinese medicine is dug to be discovered, and the traditional Chinese medicine has important practical significance for preventing and treating the new coronary pneumonia and preventing and treating epidemic diseases in the future.
Disclosure of Invention
In order to realize effective treatment of the traditional Chinese medicine on patients with the novel coronavirus pneumonia, particularly ordinary, light and asymptomatic infected patients, the invention provides a traditional Chinese medicine composition for treating the novel coronavirus pneumonia, and the adopted technical scheme is as follows:
a traditional Chinese medicine composition for treating neocoronary pneumonia comprises the following raw materials in parts by weight:
13-28 parts of astragalus membranaceus, 6-25 parts of fried bighead atractylodes rhizome, 7-24 parts of divaricate saposhnikovia root, 4-26 parts of honeysuckle, 7-27 parts of fructus forsythiae, 6-23 parts of mangnolia officinalis and 3-18 parts of honey-fried licorice root.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
10-25 parts of astragalus membranaceus, 8-20 parts of fried bighead atractylodes rhizome, 8-20 parts of divaricate saposhnikovia root, 8-20 parts of honeysuckle, 8-18 parts of fructus forsythiae, 7-15 parts of mangnolia officinalis and 3-10 parts of honey-fried licorice root.
More preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
15 parts of astragalus membranaceus, 10 parts of fried bighead atractylodes rhizome, 10 parts of divaricate saposhnikovia root, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 10 parts of mangnolia officinalis and 5 parts of honey-fried licorice root.
Preferably, the important composition also comprises radix codonopsitis and ageratum, the parts by weight are respectively as follows: 11-28 parts of codonopsis pilosula and 7-26 parts of wrinkled gianthyssop herb.
More preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight:
10-25 parts of astragalus membranaceus, 8-20 parts of fried bighead atractylodes rhizome, 13-23 parts of codonopsis pilosula, 8-20 parts of divaricate saposhnikovia root, 8-20 parts of honeysuckle, 8-18 parts of fructus forsythiae, 7-15 parts of mangnolia officinalis, 8-16 parts of wrinkled gianthyssop herb and 3-10 parts of honey-fried licorice root.
More preferably, the feed comprises the following raw materials in parts by weight:
15 parts of astragalus membranaceus, 10 parts of fried bighead atractylodes rhizome, 15 parts of codonopsis pilosula, 10 parts of divaricate saposhnikovia root, 10 parts of honeysuckle flower, 10 parts of fructus forsythiae, 10 parts of mangnolia officinalis, 10 parts of wrinkled gianthyssop herb and 5 parts of honey-fried licorice root.
Another objective of the present invention is to provide a method for preparing the above-mentioned Chinese medicinal composition, which comprises the following steps:
(1) weighing each traditional Chinese medicine according to parts by weight, and cleaning and selecting for later use;
(2) putting the medicinal materials for standby in the step (1) into a container, adding water, soaking for 20-60 min, and taking out for standby after soaking;
(3) putting the Chinese medicinal materials soaked in the step (2) into a decocting container, adding water until the surface of the Chinese medicinal materials is submerged for 3-5 cm, boiling with strong fire, and then continuously decocting with slow fire for 25 min;
(4) and (4) adding water into the medicine mixture which is decocted for the first time in the step (3) until the water is 1-2 cm higher than the medicine surface, boiling with strong fire, then continuously boiling with slow fire for 20min, and removing residues to obtain the traditional Chinese medicine composition decoction.
Preferably, the honeysuckle flower in the step (2) is soaked for 20-30 min, and other traditional Chinese medicines are soaked for 50-60 min.
The traditional Chinese medicine composition can be applied to preparation of a medicine for treating neocoronary pneumonia.
Preferably, the first three traditional Chinese medicine compositions are applied to the preparation of medicines for treating patients with mild new coronary pneumonia or asymptomatic infected patients.
Preferably, the latter three traditional Chinese medicine compositions are applied to the preparation of medicines for treating patients with common type new coronary pneumonia.
Radix astragali is root of Astragalus mongholicus (Astragalus mongholicus Bunge) belonging to Leguminosae. The production is widely cultivated in inner Mongolia, Shanxi and Heilongjiang. Sweet in flavor and slightly warm in nature; it enters spleen and lung meridians. Astragalus root can be used as a medicine, has sweet taste and mild nature, has the effects of invigorating qi, consolidating superficial resistance, promoting urination, strengthening heart, lowering blood pressure, resisting bacteria, expelling toxin, expelling pus, promoting granulation, enhancing capillary vessel resistance, arresting sweating and sex hormone-like effects, and can be used for treating exterior deficiency spontaneous perspiration, internal injury due to qi deficiency, spleen deficiency diarrhea, edema, carbuncle and cellulitis, etc. Modern researches have shown that radix astragali contains astragaloside IV and Astragalus polysaccharides. The astragalus polysaccharides have the functions of reducing blood fat, namely reducing cholesterol and triglyceride and increasing high-density lipoprotein; can be used for preventing and treating cardiovascular and cerebrovascular diseases, such as atherosclerosis, coronary artery disease, peripheral angiopathy, and hyperlipidemia. Astragaloside IV has effects of remarkably reducing blood sugar, glycosylated hemoglobin and urine protein, and reducing AGEs in renal cortex and blood serum, and has effects of resisting oxidation, inhibiting aldose reductase, inhibiting mesangial cell proliferation, and relieving renal hypertrophy. Proper auxiliary materials are added into the astragaloside IV to prepare an oral preparation which is used for preventing and treating diabetic nephropathy.
Atractylodis rhizoma, rhizome of Atractylodes macrocephala Koidz of Compositae, is distributed in Jiangsu, Zhejiang, Fujian, Jiangxi, Anhui, Sichuan, Hubei and Hunan. Is bitter, warm and pungent in property, has the effects of strengthening spleen, tonifying qi, eliminating dampness, promoting diuresis, arresting sweating and preventing miscarriage, and is used for treating spleen deficiency, anorexia, abdominal distention, diarrhea, phlegm retention, palpitation, edema, spontaneous perspiration and threatened abortion. Modern research shows that the rhizoma atractylodis macrocephalae contains 1.4% of volatile oil, wherein the oil mainly contains atractylone, atractylol ether, juniper camphor, atractyloide and the like, and also contains fructose, inulin, rhizoma atractylodis macrocephalae polysaccharide, various amino acids, vitamin A ingredients and the like. The atractylodes macrocephala has a bidirectional regulating effect on the intestinal canal activity, and shows an inhibiting effect when the intestinal canal is excited, and shows an exciting effect when the intestinal canal is inhibited; the white atractylodes rhizome has a certain function of improving leucocytes; atractylodis rhizoma has effects in protecting liver, promoting bile flow, promoting urination, lowering blood sugar, resisting blood coagulation, resisting bacteria, and resisting tumor; the volatile oil of Atractylodis rhizoma has tranquilizing effect; atractylodis rhizoma has effects in preventing and treating gastric ulcer and resisting bacteria; the rhizoma Atractylodis Macrocephalae water extract has inhibitory effect on Epidermophyton floccosum and Nocardia stellatoides in test tube; the decoction also has inhibitory effect on meningococcus; the bighead atractylodes rhizome has the strengthening effect: can increase body weight, promote the synthesis of small intestine protein, and promote cellular immunity.
Codonopsis pilosula (Codonopsis) of Codonopsis genus (Codonopsis pilosula (Franch.) Nannf), Campanulaceae family, perennial herbs and milky juice. Elevation 1560-. Codonopsis pilosula is sweet in flavor and neutral in nature. Has effects in invigorating spleen, replenishing qi, quenching thirst, invigorating spleen, benefiting lung, nourishing blood, and promoting salivation. Can be used for treating deficiency of spleen-lung qi, anorexia, listlessness, cough, asthma, deficiency of qi and blood, color of face, turmeric, palpitation, short breath, thirst due to body fluid consumption, and internal heat. Modern research shows that radix Codonopsis contains polysaccharide, phenols, sterol, volatile oil, baicalein glucoside, trace alkaloids, inulin, and saponin. Radix Codonopsis has anticancer, blood pressure lowering, anoxia resisting, antiaging, antiulcer, immunity enhancing, gastrointestinal motility regulating, gastric acid secretion inhibiting, and pepsin activity reducing effects.
Radix Saposhnikoviae, root of Saposhnikovia divaricata (Turcz.) Schischk of Umbelliferae, perennial herb. It is originated from grassland, hilly land and hillside with many gravels. Distributed in Heilongjiang, Jilin, Liaoning, inner Mongolia and other places. Warm in nature, sweet and pungent in flavor. It enters bladder meridian, spleen meridian and liver meridian. It is used for relieving exterior syndrome, dispelling wind and removing dampness, and belongs to the category of exterior-releasing herbs with pungent and warm properties. Modern researches have the effects of relieving fever and cooling, easing pain and calming, resisting convulsion, resisting bacteria and resisting inflammation; enhancing immune system function; inhibiting contraction of isolated duodenum, isolated trachea and ileocecal smooth muscle; an antihistamine; and (4) anticoagulation. The divaricate saposhnikovia root decoction or the alcohol infusion is used for gastric lavage of rabbits or intraperitoneal injection of rats, and has antipyretic effect; the mouse is infused with the decoction of radix Saposhnikoviae and ethanol infusion for relieving pain; the n-butanol extract is injected into the muscle, so that the blood viscosity of the rat can be reduced; the radix Saposhnikoviae decoction, ethanol infusion, or abdominal cavity administration has antiinflammatory and immunity enhancing effects for rat and mouse. The radix Saposhnikoviae decoction has antibacterial and antiviral effects.
Honeysuckle, which is a dry bud or a flower with a first blossom of Lonicera japonica Thumb (Lonicera japonica Thumb) of Caprifoliaceae, is distributed in China, and the planting areas of honeysuckle are mainly concentrated in Shandong, Shaanxi, Henan, Hebei, Hubei, Jiangxi, Guangdong and other places. Sweet and cold in nature, entering lung and stomach channels, clearing heat and removing toxicity, diminishing inflammation and relieving swelling, and mainly treating exogenous wind-heat or warm disease fever, heatstroke, heat-toxin and bloody dysentery, carbuncle, swelling, furuncle, pharyngitis and various infectious diseases. Modern researches prove that the main chemical components of the honeysuckle flower comprise volatile oil, organic acid, flavone, iridoid, triterpenoid saponin, inorganic elements and the like, and a plurality of experiments and clinical researches prove that the honeysuckle flower has obvious inhibiting effect on influenza virus, herpes virus, adenovirus, syncytial virus and the like and has obvious curative effect on viral diseases such as viral myocarditis and the like.
Forsythia suspensa (Forsythoa subspina (Thunb.) Vahl), a fruit of Forsythoa subspina (Forsythoa subspina, Oleaceae). Produced in the northeast, north China, Yangtze river flow city to Yunnan. Bitter, pungent and slightly cold. Enter lung, heart and gallbladder meridians. Has the effects of clearing away heat and toxic materials, eliminating carbuncle, dispersing pathogenic accumulation, and dispelling pathogenic wind and heat. Mainly treats carbuncle, sore, scrofula and subcutaneous nodule; affection of exogenous wind-heat, early onset of warm disease; heat stranguria, astringing pain, etc. Modern researches show that forsythoside extracted from fructus forsythiae has the effects of relieving fever, resisting infection and eliminating active oxygen.
Magnolia officinalis, the dry bark, root bark and branch bark of Magnolia officinalis (Magnolia officinalis Rehd. et Wils) or Magnolia officinalis (M. officinalis Rehd. et Wils) belonging to the family Magnoliaceae and the family Lauraceae. Produced in Sichuan, Hubei, Anhui, etc. Bitter in taste and pungent in nature. Enter spleen, stomach, lung and large intestine meridians. Has the effects of promoting qi circulation, eliminating dampness, removing food retention, and relieving asthma. Mainly treats dampness obstruction of middle energizer and qi stagnation; food stagnation in the stomach and intestines, abdominal distention and fullness, constipation; cough and asthma due to phlegm-fluid retention. Modern researches have shown that magnolol and honokiol extracted from cortex Magnolia officinalis have antifungal, angiogenesis inhibiting and tumor growth inhibiting, Cyclooxygenase (COX) and lipoxygenase ((LO) inhibiting, and ventricular arrhythmia induced by ischemia and reperfusion.
Agastache rugosa, aerial parts of the perennial herb Pogostemon cablin Blanco Benth (Labiatae). Produced in the Guangdong province. Pungent and warm in flavor. Enter spleen, stomach and lung meridians. Has effects in eliminating dampness, relieving summer-heat, and relieving vomit. Mainly treats damp obstruction of middle energizer; stagnation of intestine and stomach, summer-heat-dampness syndrome and early stage of damp-warm disease; vomiting, etc. Modern researches show that the herba Agastaches water extract and ethanol extract have antibacterial, antiviral, antiinflammatory and analgesic effects, and also have effects of inhibiting gastrointestinal motility, protecting gastrointestinal mucosa, promoting gastric acid secretion, and improving pepsin activity.
Glycyrrhrizae radix, root and rhizome of Glycyrrhiza uralensis Fisch (Glycyrrhiza uralensis Fisch), Glycyrrhiza inflata Bat (Glycyrrhiza inflata Bat) or Glycyrrhiza glabra L (Glycyrrhiza glabra L) belonging to the family Leguminosae. The main local origins are inner Mongolia, Shanxi, Gansu, Xinjiang, etc. Sweet in flavor and neutral in nature. Enter heart, lung, spleen and stomach meridians. Has the effects of tonifying qi and strengthening the middle warmer, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing drug properties. Mainly treats heart-qi deficiency and spleen-qi deficiency: palpitation, intermittent pulse, lassitude, poor appetite and loose stool; cough with profuse sputum; spasm and pain of the abdomen and limbs; sores and ulcers due to heat-toxin, swollen and sore throat, and poisoning due to drugs and food. Modern researches have shown that glycyrrhizic acid extracted from licorice has antiviral, antiinflammatory and antitumor effects, and in addition, licoflavone extracted from licorice has antiarrhythmic effect, and Glycyrrhiza polysaccharide has immunity regulating effect.
Compared with the prior art, the invention has the following beneficial effects:
the traditional Chinese medicine composition comprises the components of astragalus, fried bighead atractylodes rhizome, codonopsis pilosula, divaricate saposhnikovia root, honeysuckle, fructus forsythiae, mangnolia officinalis, agastache rugosus and honey-fried licorice root. Wherein, the astragalus root has the functions of tonifying qi, consolidating superficial resistance, expelling toxin, expelling pus, promoting urination and promoting granulation; radix Codonopsis is effective in invigorating qi, invigorating spleen and nourishing stomach; the stir-fried white atractylodes rhizome is matched with the drugs for strengthening the spleen and eliminating dampness to strengthen the qi and spleen tonifying capability of the codonopsis pilosula; adjuvant drugs to strengthen the spleen and regulate the middle warmer, moisten lung and remove toxicity, and harmonize the drugs in all aspects. The four herbs are mutually reinforced and make mutual reinforcement to promote the generation of gold and strengthen the body resistance to rescue adverse qi. Radix Saposhnikoviae has effects in dispelling pathogenic wind, relieving exterior syndrome, and eliminating dampness to eliminate pathogenic factors; the honeysuckle and the forsythia are matched to clear away heat and toxic material and reduce swelling, and enhance the efficacy of dispelling wind and relieving exterior syndrome; herba Agastaches and cortex Magnolia officinalis can eliminate dampness, activate spleen, eliminate dampness and eliminate phlegm. In conclusion, the traditional Chinese medicine composition has complete monarch, minister, assistant and guide components, precise compatibility and complementary effects, and has the effects of tonifying qi, detoxifying, clearing damp and relieving exterior syndrome. The composition can be used for treating the novel coronavirus pneumonia.
Compared with other traditional Chinese medicine compositions for treating the new coronary pneumonia, the invention adopts completely different treatment rules, and creatively provides the treatment rules of 'banking up and engendering gold, rescuing from the adverse qi and strengthening the body resistance'. The clinical manifestations of the novel coronavirus pneumonia mainly comprise fever, dry cough and hypodynamia, a few patients have symptoms such as nasal obstruction, watery nasal discharge, myalgia, diarrhea and the like, the main disease position is lung and spleen, and based on the basis, the principle of 'earthing up and engendering gold' is adopted, and the clinical treatment method for treating lung qi weakness is achieved by tonifying spleen qi. The inventor reported that "the human body suffered from qi in the valley according to the cloud of Ling Shu Ying health Association. The cereal enters the stomach and spreads to the lung, while the five zang-fu organs all receive qi. The clear part is the nutrient, while the turbid part is the defense. The record of the invention can tonify defensive qi by banking up earth and generating gold to tonify and strengthen the spleen and stomach, and can tonify defensive qi by assisting lung qi in diffusing and benefiting lung qi, so as to achieve the effect of preventing invasion of exogenous pathogenic factors, namely that the healthy qi exists inside and the pathogenic factors cannot dry, thereby playing an important role in novel medicaments for preventing coronavirus pneumonia or turning yin of asymptomatic infected persons. On the one hand, the prevention period of medication focuses on the reinforcement of earth and generation of gold, and the spleen and stomach are protected, so that the treatment is a cut-off treatment, namely, the treatment is combined with the idea of 'firstly relieving the place without being affected by pathogenic factors'. On the other hand, the prevention period focuses on "banking up and producing gold", which is a method for preventing the combination of internal and external pathogens.
Meanwhile, the new coronary pneumonia is vulnerable to lung qi, and the treatment and the maintenance of healthy qi are very necessary. The existing clinical report indicates that the disease condition of old people and people with low immunity is easy to aggravate and even die among patients with new coronary pneumonia, so that the acute deficiency syndrome is an important pathogenesis of severe and death caused by the new coronary pneumonia. Based on the condition, the pathological condition of rapid consumption of healthy qi caused by sudden infection of six excesses and pestilence or acute severe poisoning, blood loss, fluid loss, trauma is the most common and serious pathological form of the conflict between healthy qi and pathogenic factors in clinical critical illness. The rapid decline of yin and yang, qi and blood, and visceral functions at this stage due to various reasons is manifested as "the excessive pathogenic factors are not removed and the healthy qi is deficient", and has the characteristics of acute onset, severe disease condition, and low survival rate. Aiming at the characteristic of excessive deficiency of emergency, the traditional Chinese medicine treatment of the new coronary pneumonia adopts a method of strengthening the body resistance and rescuing the patient from the adverse side, so that the cure rate of the new coronary pneumonia can be effectively improved, the hospitalization days are shortened, the conversion rate from mild to severe symptoms is reduced, the death rate of critically ill patients is reduced, the recovery treatment of the patients is guided, and the prognosis is improved.
Detailed Description
The present invention will be further described with reference to the following specific examples, but the present invention is not limited to these examples.
The materials, reagents, methods, apparatuses, etc. used in the following examples are, without being specifically described, all materials, reagents, methods, apparatuses, etc. which are conventional in the art. Those skilled in the art are commercially available.
The various herbs used in the examples below are conventional in the art and are commercially available to those skilled in the art.
The compositions used in the following examples were prepared as follows:
(1) weighing each traditional Chinese medicine according to the parts by weight, and cleaning and selecting for later use;
(2) putting the medicinal materials for standby in the step (1) into a container, adding water, soaking for 20-60 min, and taking out for standby after soaking;
(3) putting the Chinese medicinal materials soaked in the step (2) into a decocting container, adding water until the surface of the Chinese medicinal materials is submerged for 3-5 cm, boiling with strong fire, and then continuously decocting with slow fire for 25 min;
(4) and (4) adding water into the medicine mixture which is decocted for the first time in the step (3) until the water is 1-2 cm higher than the medicine surface, boiling with strong fire, then continuously boiling with slow fire for 20min, and removing residues to obtain the traditional Chinese medicine composition decoction.
Example 1
The embodiment provides a traditional Chinese medicine composition suitable for treating a patient with mild new coronary pneumonia or helping an asymptomatic infected person to turn negative, and the composition comprises the following components in parts by weight:
13 parts of astragalus membranaceus, 6 parts of fried bighead atractylodes rhizome, 7 parts of divaricate saposhnikovia root, 4 parts of honeysuckle, 7 parts of fructus forsythiae, 6 parts of mangnolia officinalis and 3 parts of honey-fried licorice root.
Example 2
The embodiment provides a traditional Chinese medicine composition suitable for treating a patient with mild new coronary pneumonia or helping an asymptomatic infected person to turn negative, and the composition comprises the following components in parts by weight:
28 parts of astragalus membranaceus, 25 parts of fried bighead atractylodes rhizome, 24 parts of divaricate saposhnikovia root, 26 parts of honeysuckle, 27 parts of fructus forsythiae, 23 parts of mangnolia officinalis and 18 parts of honey-fried licorice root.
Example 3
The embodiment provides a traditional Chinese medicine composition suitable for treating a patient with mild new coronary pneumonia or helping an asymptomatic infected person to turn negative, and the composition comprises the following components in parts by weight:
15 parts of astragalus membranaceus, 10 parts of fried bighead atractylodes rhizome, 10 parts of divaricate saposhnikovia root, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 10 parts of mangnolia officinalis and 5 parts of honey-fried licorice root.
Example 4
The embodiment provides a traditional Chinese medicine composition suitable for treating common patients with new coronary pneumonia, which comprises the following components in parts by weight:
13 parts of astragalus membranaceus, 6 parts of fried bighead atractylodes rhizome, 11 parts of codonopsis pilosula, 7 parts of divaricate saposhnikovia root, 4 parts of honeysuckle, 7 parts of fructus forsythiae, 6 parts of mangnolia officinalis, 7 parts of wrinkled gianthyssop herb and 3 parts of honey-fried licorice root.
Example 5
The embodiment provides a traditional Chinese medicine composition suitable for treating common patients with new coronary pneumonia, which comprises the following components in parts by weight:
28 parts of astragalus membranaceus, 25 parts of fried bighead atractylodes rhizome, 28 parts of codonopsis pilosula, 24 parts of divaricate saposhnikovia root, 26 parts of honeysuckle flower, 27 parts of fructus forsythiae, 23 parts of mangnolia officinalis, 26 parts of wrinkled gianthyssop herb and 18 parts of honey-fried licorice root.
Example 6
The embodiment provides a traditional Chinese medicine composition suitable for treating common patients with new coronary pneumonia, which comprises the following components in parts by weight:
15 parts of astragalus membranaceus, 10 parts of fried bighead atractylodes rhizome, 15 parts of codonopsis pilosula, 10 parts of divaricate saposhnikovia root, 10 parts of honeysuckle flower, 10 parts of fructus forsythiae, 10 parts of mangnolia officinalis, 10 parts of wrinkled gianthyssop herb and 5 parts of honey-fried licorice root.
Example 7
The applicant organizes the inventor to participate in a new round of crown epidemic outbreak in 1 month of 2021 from quanzhike county, the Suizhihua city of Heilongjiang province. 415 patients were treated in a cumulative manner, with 206 patients (light 143, normal 45, heavy 18, critical 0), 209 asymptomatic infected patients and no death. All patients take the traditional Chinese medicine composition of the application within 4 hours of admission, namely light patients take the traditional Chinese medicine composition of the example 3, and ordinary and heavy patients take the traditional Chinese medicine composition of the example 6, and the traditional Chinese medicine composition is taken twice a day, in the morning and evening for treatment, the utilization rate is 100%, and the treatment is completely covered. After 10 to 14 days of treatment, the nucleic acid detection of the patient is completely converted into negative, and the patient has no nucleic acid and has a positive again.
Clinical symptoms of admission in confirmed case 206 are shown in table 1. The symptom disappearance and improvement of the confirmed cases are shown in Table 2. The outcome of confirmed patients and asymptomatic patients is shown in Table 3. In addition, during the treatment, 206 patients with confirmed diagnosis were divided into 10 groups, one patient was randomly selected from each group, and five indices of blood oxygen saturation, leukocyte, lymphocyte percentage, neutrophil percentage and albumin before and after the treatment were measured, and the measurement results are shown in tables 4 and 5.
TABLE 1 clinical symptom profile of confirmed cases
TABLE 2 clinical symptom disappearance of confirmed cases
TABLE 3 prognosis of confirmed patients and asymptomatic infected persons
TABLE 4 patient indices in different groups before treatment
TABLE 5 patient indices in different groups after treatment
As can be seen from tables 1-5, the formula of the traditional Chinese medicine composition of the present application has significant efficacy in treating new coronary pneumonia, especially for light and common patients.
Typical case one
The patient is in Taoqin, male, 63 years old, and living in Taoqin county for a long time, and enters the family 1, 15 days in 2021 because the novel coronavirus is screened positive. The patient is isolated and then transferred to a Homing county hospital, and the patient is given oral Chinese medicinal liquid for 1 day during hospital stay, the effect is poor, and the patient is transferred to the Homing to continue isolated observation and treatment, and is checked for the patient at present: the body temperature is 37.1 ℃, the pulse is 60 times/min, the breath is 18 times/min, the blood pressure is 160/120mmHg, the patient has clear mind, moderate nutrition, painful expression and rapid respiration, and the auscultation cannot be performed due to the isolation clothes, the sleep is poor, and the stool and the urine are normal. And (4) checking: blood conventional WBC4.40 × 109Per L, NEU 3.50X 109n/L, LY 12.2X 109Per liter, C-reactive protein (CRP)87.91 mg.L-1, arterial blood gas (T37 ℃ C.) pH 7.456, PCO234.6mmHg, partial pressure of blood oxygen (PO)2)81.0mmHg，HCO3 23.8mmol·L-1，SO292.3 percent, 2.3 mmol.L-1 of lactic acid (Lac); ALT 46 U.L-1, AST 35 U.L-1, glutamyl transpeptidase (GGT)43 U.L-1, Total Protein (TP)56 g.L-1, Albumin (ALB)35 g.L-1, potassium 4.6 mmol.L-1; chest CT: the inflammation of both lungs is markedly aggravated earlier. Pathogenic examination the novel coronavirus nucleic acid test is positive. Admission diagnosis: novel coronavirus pneumonia (common type), and hypertension. Non-invasive ventilator assisted ventilation is carried out after hospital admission, the arbidol hydrochloride is used for supporting and treating the symptoms such as antivirus, interferon alpha-2 b needle, acetylcysteine and budesonide suspension atomization inhalation, potassium citrate granules, ambroxol, doxofylline and potassium aspartate, electrolyte disorder correction and the like. The first diagnosis of traditional Chinese medicine: fever, body temperature 37 deg.C, clear mind, moderate nutrition, expression pain, dry cough, little phlegm, short breath, shortness of breath, poor appetite, red tongue with yellow coatingThick, slippery and rapid pulse, belonging to epidemic toxicity blocking lung, and indicated for qi-tonifying and yin-nourishing, heat-clearing and toxicity-removing, cough-relieving, phlegm-eliminating and asthma-relieving, the prescription is: 15g of astragalus, 10g of fried bighead atractylodes rhizome, 15g of codonopsis pilosula, 10g of divaricate saposhnikovia root, 10g of honeysuckle flower, 10g of weeping forsythia, 10g of magnolia officinalis, 10g of wrinkled gianthyssop herb and 5g of honey-fried licorice root. Five doses, twice a day, are decocted with water for warm taking in the morning and evening. After the patient takes the medicine in 2021 year, 1 month and 20 days, the body temperature of the patient is reduced, 36.6 ℃, the heart rate is 80 times/min, the patient has diarrhea for 2-4 times per day, the emotion is stable, the dyspnea is relieved, the dry cough and the short breath symptoms are relieved, more white foam sticky phlegm is coughed out, the stable blood oxygen saturation is maintained at 90% -95% under the non-invasive mechanical ventilation, and the traditional Chinese medicine is continuously used above. 25 days at 1 month in 2021, the patient is clear in mind, poor spirit and obvious in relieving dyspnea, white foam sticky phlegm is produced in the cough, diet is normal, stool is normal, the traditional Chinese medicine is continuously taken, 15g of astragalus mongholicus, 10g of fried bighead atractylodes rhizome, 10g of divaricate saposhnikovia root, 10g of honeysuckle, 10g of fructus forsythiae, 10g of mangnolia officinalis and 5g of honey-fried licorice root are taken, and the treatment lasts for 2 days. In 2021, month 1 and day 27, the patients had clear mind, normal spirit, normal diet, normal stool and obviously improved dyspnea. Physical examination: body temperature 36.3 ℃, pulse 70 times/min, respiration 21 times/min, blood pressure 130/85mm Hg, blood routine laboratory test: WBC 7.21X 1092.91X 10 RBC/L12Per liter, hemoglobin 90 g.L-1，SO2Stabilizing to 94-97%, transforming nucleic acid to negative, discharging the patient, and ordering the patient to make a periodic re-diagnosis.
Typical case two
The patient, namely the patient, is a plum woman of 80 years old, is diagnosed as new coronavirus infection at 1 month and 14 days after the whole village nucleic acid is screened to be detected completely, and is sent to the hospital at 1 month and 15 days of 2021 year, and is admitted to the hospital as the new coronavirus infection. Admission to the examinee: the body temperature is 36.3 ℃, the pulse is 84 times/min, the breath is 18 times/min, and the blood pressure is 125/72 mmHg. The patient has clear mind, poor spirit, emaciation, anorexia and normal defecation. CT of chest shows: two lung interstitial changes are combined with infection, and auxiliary examination is carried out: blood routine shows WBC 6.27X 109/L, RBC 4.94X 1012/L, hemoglobin 150.0 g.L-1, NEU percent 83.0%, LY 0.85X 109/L. CT of the chest shows two lungs with multiple lamellar foci of infection. ALT 23 U.L-1, AST 47 U.L-1, glutamyl transpeptidase (GGT)65 U.L-1, Total Protein (TP)57 g.L-1, Albumin (ALB)35.1 g.L-1, potassium 3.4 mmol.L-1; novel coronavirus nucleic acid detection positive. During the treatment period, patients still have intermittent fever, cough and hypodynamia. Abidol hydrochloride, a human immunoglobulin needle (4.5g, 1 time/8 h), a methylprednisolone needle (40mg, 1 time/12 h), Xuebijing (100mL, 1 time/12 h) and ambroxol are used for symptomatic treatment and noninvasive ventilator assisted ventilation. The first diagnosis in 2021, 1, 17 days of traditional Chinese medicine: the patient is fever, the body temperature is 38 ℃, dry cough is short of phlegm, shortness of breath, dysphoria, panic, anorexia, mental fatigue and hypodynamia, no appetite, red tongue, yellow and thick tongue coating and slippery and rapid pulse, which belong to epidemic toxin lung blocking and are treated by tonifying qi and nourishing yin, clearing heat and detoxicating, relieving cough and eliminating phlegm and relieving asthma, and the prescription is as follows: 15g of astragalus, 10g of fried bighead atractylodes rhizome, 15g of codonopsis pilosula, 10g of divaricate saposhnikovia root, 10g of honeysuckle flower, 10g of weeping forsythia, 10g of magnolia officinalis, 10g of wrinkled gianthyssop herb and 5g of honey-fried licorice root. Three doses, 1 dose daily, are decocted with water for warm oral administration in the morning and evening. After the patient takes the medicine in 2021 year, 1 month and 20 days, the body temperature of the patient is reduced, 36.8 ℃, the heart rate is 60 times/min, the patient has diarrhea for 2-4 times every day, the emotion is stable, the dyspnea is slightly relieved, dry cough, short breath and more white foam phlegm are produced, the stable blood oxygen saturation is maintained at 90% -95% under the non-invasive mechanical ventilation, and the traditional Chinese medicine is continuously used above. 24 days at 1 month in 2021, the patient is refreshed, has bad mind and respiratory distress, expectorates white foam phlegm, anorexia, diarrhea 3 times daily, discharges yellow and watery stool at night, and continues to take traditional Chinese medicines 2 times/d for treatment 2 d. On the 4 th month 2 in 2021, the patient has a clear mind, improved spirit, improved appetite, reduced diarrhea and reduced respiratory distress. Blood routine test examination: WBC 8.61X 109cell/L, RBC 4.32X 1012Per liter, 100 g.L of hemoglobin-1，SO2When the concentration is 90-95%, the nucleic acid turns negative, and the patient is discharged, and the patient is ordered to make a periodic re-diagnosis.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. A traditional Chinese medicine composition for treating neocoronary pneumonia is characterized by comprising the following raw materials in parts by weight:
13-28 parts of astragalus membranaceus, 6-25 parts of fried bighead atractylodes rhizome, 7-24 parts of divaricate saposhnikovia root, 4-26 parts of honeysuckle, 7-27 parts of fructus forsythiae, 6-23 parts of mangnolia officinalis and 3-18 parts of honey-fried licorice root.
2. The traditional Chinese medicine composition for treating neocoronary pneumonia according to claim 1, which is characterized by comprising the following raw materials in parts by weight:
13-25 parts of astragalus membranaceus, 8-20 parts of fried bighead atractylodes rhizome, 8-20 parts of divaricate saposhnikovia root, 8-20 parts of honeysuckle, 8-18 parts of fructus forsythiae, 7-15 parts of mangnolia officinalis and 3-10 parts of honey-fried licorice root.
3. The traditional Chinese medicine composition for treating neocoronary pneumonia according to claim 2, which is characterized by comprising the following raw materials in parts by weight:
15 parts of astragalus membranaceus, 10 parts of fried bighead atractylodes rhizome, 10 parts of divaricate saposhnikovia root, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 10 parts of mangnolia officinalis and 5 parts of honey-fried licorice root.
4. The traditional Chinese medicine composition for treating neocoronary pneumonia according to claim 1, further comprising radix codonopsis pilosulae 11-28 parts and wrinkled giant hyssop 7-26 parts.
5. The traditional Chinese medicine composition for treating neocoronary pneumonia according to claim 4, which is characterized by comprising the following raw materials in parts by weight:
13-25 parts of astragalus membranaceus, 8-20 parts of fried bighead atractylodes rhizome, 13-23 parts of codonopsis pilosula, 8-20 parts of divaricate saposhnikovia root, 8-20 parts of honeysuckle, 8-18 parts of fructus forsythiae, 7-15 parts of mangnolia officinalis, 8-16 parts of wrinkled gianthyssop herb and 3-10 parts of honey-fried licorice root.
6. The traditional Chinese medicine composition for treating neocoronary pneumonia according to claim 5, is characterized by comprising the following raw materials in parts by weight:
15 parts of astragalus membranaceus, 10 parts of fried bighead atractylodes rhizome, 15 parts of codonopsis pilosula, 10 parts of divaricate saposhnikovia root, 10 parts of honeysuckle flower, 10 parts of fructus forsythiae, 10 parts of mangnolia officinalis, 10 parts of wrinkled gianthyssop herb and 5 parts of honey-fried licorice root.
7. The preparation method of the traditional Chinese medicine composition of any one of claims 1 to 6, which is characterized by comprising the following steps:
(1) weighing each traditional Chinese medicine according to parts by weight, and cleaning and selecting for later use;
(2) putting the medicinal materials for standby in the step (1) into a container, adding water, soaking for 20-60 min, and taking out for standby after soaking;
(3) putting the Chinese medicinal materials soaked in the step (2) into a decocting container, adding water until the surface of the Chinese medicinal materials is submerged for 3-5 cm, boiling with strong fire, and then continuously decocting with slow fire for 25 min;
(4) and (4) adding water into the medicine mixture which is decocted for the first time in the step (3) until the water is 1-2 cm higher than the medicine surface, boiling with strong fire, then continuously boiling with slow fire for 20min, and removing residues to obtain the traditional Chinese medicine composition decoction.
8. The use of the Chinese medicinal composition of any one of claims 1-6 in the preparation of a medicament for the treatment of neocoronary pneumonia.
9. The use of claim 8, wherein the use of the Chinese medicinal composition of claims 1-3 in the preparation of a medicament for treating a patient with mild new coronary pneumonia or an asymptomatic infected patient.
10. The use of claim 8, wherein the use of the Chinese medicinal composition of claims 4-6 in the preparation of a medicament for treating patients with common neocoronary pneumonia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110853779.1A CN113577140A (en) | 2021-07-28 | 2021-07-28 | Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110853779.1A CN113577140A (en) | 2021-07-28 | 2021-07-28 | Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113577140A true CN113577140A (en) | 2021-11-02 |
Family
ID=78250808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110853779.1A Pending CN113577140A (en) | 2021-07-28 | 2021-07-28 | Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577140A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617940A (en) * | 2022-04-07 | 2022-06-14 | 北京中医药大学深圳医院(龙岗) | Traditional Chinese medicine composition for preventing new coronavirus pneumonia and preparation method thereof |
| CN115040619A (en) * | 2022-05-27 | 2022-09-13 | 博济医药科技股份有限公司 | A Chinese medicinal composition and its application in preparing medicine for treating pneumonia |
| CN115814033A (en) * | 2022-06-27 | 2023-03-21 | 天圣制药集团股份有限公司 | Traditional Chinese medicine composition for preventing, relieving or treating new coronary pneumonia and pharmaceutical application thereof |
| CN116196363A (en) * | 2022-09-30 | 2023-06-02 | 四川省中医药科学院 | Traditional Chinese medicine composition for treating viral pneumonia and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309541A (en) * | 2015-06-26 | 2017-01-11 | 孙惠红 | Traditional Chinese medicine composition for prevention and treatment of susceptible-to-cold physique |
| CN111249390A (en) * | 2020-03-12 | 2020-06-09 | 尧舜泽生物医药(南京)有限公司 | Forsythia-astragalus root compound preparation and preparation method and application thereof |
| CN112022905A (en) * | 2020-07-10 | 2020-12-04 | 贵州中医药大学第一附属医院 | Medicine for protecting novel coronavirus susceptible population and preparation method thereof |
-
2021
- 2021-07-28 CN CN202110853779.1A patent/CN113577140A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309541A (en) * | 2015-06-26 | 2017-01-11 | 孙惠红 | Traditional Chinese medicine composition for prevention and treatment of susceptible-to-cold physique |
| CN111249390A (en) * | 2020-03-12 | 2020-06-09 | 尧舜泽生物医药(南京)有限公司 | Forsythia-astragalus root compound preparation and preparation method and application thereof |
| CN112022905A (en) * | 2020-07-10 | 2020-12-04 | 贵州中医药大学第一附属医院 | Medicine for protecting novel coronavirus susceptible population and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 周朴帆等: "浅析老年人新型冠状病毒肺炎的认识与防范", 《中华老年多器官疾病杂志》 * |
| 曲金桥等: "论中医药防治新型冠状病毒感染肺炎优势与特色", 《辽宁中医药大学学报》 * |
| 李妲等: "新型冠状病毒肺炎对心血管系统影响的中医认识与防治策略", 《中国动脉硬化杂志》 * |
| 秦裕辉等: "新冠系列方预防新型冠状病毒感染用方探讨", 《湖南中医药大学学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617940A (en) * | 2022-04-07 | 2022-06-14 | 北京中医药大学深圳医院(龙岗) | Traditional Chinese medicine composition for preventing new coronavirus pneumonia and preparation method thereof |
| CN115040619A (en) * | 2022-05-27 | 2022-09-13 | 博济医药科技股份有限公司 | A Chinese medicinal composition and its application in preparing medicine for treating pneumonia |
| CN115040619B (en) * | 2022-05-27 | 2023-08-08 | 博济医药科技股份有限公司 | Traditional Chinese medicine composition and application thereof in preparation of medicine with function of treating pneumonia |
| CN115814033A (en) * | 2022-06-27 | 2023-03-21 | 天圣制药集团股份有限公司 | Traditional Chinese medicine composition for preventing, relieving or treating new coronary pneumonia and pharmaceutical application thereof |
| CN115814033B (en) * | 2022-06-27 | 2023-09-12 | 天圣制药集团股份有限公司 | Chinese medicinal composition for inhibiting novel coronavirus and pharmaceutical use thereof |
| CN116196363A (en) * | 2022-09-30 | 2023-06-02 | 四川省中医药科学院 | Traditional Chinese medicine composition for treating viral pneumonia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113577140A (en) | Traditional Chinese medicine composition for treating neocoronary pneumonia and preparation method and application thereof | |
| CN112353855A (en) | Application of traditional Chinese medicine composition in preparation of medicine for adjuvant therapy of novel coronavirus pneumonia | |
| CN102631647A (en) | Chinese patent medicine mixture for treating acute urticaria | |
| CN111569010B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating neocoronary pneumonia | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN103463449A (en) | Traditional Chinese medicine composite used for treating haemorrhoids and preparation method and application thereof | |
| CN106177392A (en) | A kind of decoction medicine treating exogenous high fever and preparation method thereof | |
| CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN105194165B (en) | Traditional Chinese medicine used for treating infection of urinary system and preparation method thereof | |
| CN104721767A (en) | Chinese medicinal composition for treatment of children cough and preparation method thereof | |
| CN111514237B (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof | |
| CN102631648A (en) | Chinese patent medicine for treating acute urticaria | |
| CN106728729A (en) | A kind of clinical anesthesia Chinese medicine preparation for gastrocopy | |
| CN102813767B (en) | First-aid drug for treating heatstroke and preparation method thereof | |
| CN105709005A (en) | Breast rehabilitation promoting pill | |
| Wang et al. | Research Progress on Recognition and Treatment of RSV Infection in Traditional Chinese Medicine | |
| CN104189199A (en) | Pharmaceutical composition for treating urinary tract infection, and preparation method | |
| CN104288637A (en) | Medicine composition with function of removing heat from lung to relieve cough | |
| CN104666468A (en) | Pharmaceutical composition for treating hyperthyroidism and scrofula | |
| CN104189868A (en) | Traditional Chinese medicine for treating bronchial asthma | |
| CN104547215A (en) | Traditional Chinese medicine composition containing centella asiatica | |
| CN104189870A (en) | Traditional Chinese medicine for treating allergic asthma | |
| CN102335327B (en) | Pharmaceutical composition for treating asthma | |
| CN102895555A (en) | Traditional Chinese medicine for treating mumps viral encephalopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211102 |
|
| RJ01 | Rejection of invention patent application after publication |